Novel Cell Therapy Delivery
Sentien Biotechnologies, Inc. is a privately owned, clinical stage company developing novel delivery approaches to cell therapy.
Our lead product is designed to allow for controlled, sustained delivery of mesenchymal stem cell (MSC) secreted factors. This approach immobilizes the
MSCs in an extracorporeal device, allowing for doses of therapeutic secreted factors that are unattainable by direct injection.
Visit Sentien Biotechnologies's website.